天津科学技术出版社
遗传性血液疾病基因治疗的新进展:从血友病到血红蛋白病的突破
徐秉岐 1,2,张磊 1,2
作者信息
  1. 1 中国医学科学院血液病医院(中国医学科学院血液学研究所),实验血液学国家重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津市血液病基因治疗研究重点实验室,中国医学科学院血液病基因治疗重点实验室,天津 300020
  2. 2 天津医学健康研究院,天津 301600
*通信作者

摘要

遗传性血液疾病如血友病、镰状细胞病、地中海贫血,给全球带来沉重的健康与社会负担,传统治疗存在终身依赖、费用高昂等局限。 基因治疗的兴起推动该领域治疗范式发生根本性变革,成为治愈此类疾病的关键方向。 (1)在载体系统方面:慢病毒载体通过优化启动子提升了安全性与表达效率,腺相关病毒(AAV)载体凭借低免疫原性和组织靶向性在血友病治疗中占据主导,新型载体通过启动子选择和整合控制进一步降低风险。基因编辑技术实现了重大突破:规律成簇间隔短回文重复序列(CRISPR)-CRISPR 相关蛋白 9(Cas9)疗法获美国食品药品监督管理局(FDA)批准用于镰状细胞贫血,碱基编辑技术可精准修正致病点突变,表观遗传编辑则通过激活胎儿血红蛋白提供新策略。 (2)临床试验成果显著:多款血友病基因治疗产品获批,β-地中海贫血患者经治疗后可脱离输血依赖,镰状细胞病基因编辑疗法有效减少了血管闭塞危象。 然而,该领域仍面临治疗成本高、儿童患者数据匮乏、疗效评估标准不统一等问题,插入突变、免疫原性和脱靶效应等安全性挑战亦需持续应对。 未来,通用型治疗平台构建、体内直接编辑技术突破及联合治疗策略探索将成为核心发展方向,推动基因治疗向个体化精准医疗迈进,为遗传性血液疾病患者带来更可及、更安全的根治希望。

Advancement of gene therapy for hereditary blood disorders:breakthroughs from hemophilia to hemoglobinopathies
Bingqi XU 1,2, Lei ZHANG 1,2 *
Author Information
  1. 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
  2. 2 Tianjin Institutes of Health Science, Tianjin 300020, China
*Corresponding author

Abstract

Hereditary blood disorders, such as hemophilia, sickle cell disease, and thalassemia, impose a heavy global health and social burden. Traditional treatments are limited by lifelong dependence and high costs. The rise of gene therapy has driven a fundamental  transformation in the treatment paradigm of this field, becoming a key direction for curing such diseases. (1) In terms of vector systems: lentiviral vectors have improved safety and expression efficiency through promoter optimization. Adeno-associated virus (AAV) vectors dominate hemophilia treatment due to their low immunogenicity and tissue targeting. Novel vectors further reduce risks through promoter selection and integration control. Gene editing technology has achieved significant breakthroughs: clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) therapy has been approved by the Food and Drug Administration (FDA) for sickle cell anemia, base editing can accurately correct pathogenic point mutations, and epigenetic editing provides a new strategy by activating fetal hemoglobin. (2) Clinical trial results are remarkable: several hemophilia gene therapy products have been approved, 茁-thalassemia patients can achieve transfusion independence after treatment, and gene editing therapy for sickle cell disease effectively reduces vaso-occlusive crises. However, the field still faces issues such as high treatment costs, lack of data on pediatric patients, and inconsistent efficacy evaluation standards. Safety challenges including insertional mutagenesis, immunogenicity, and off-target effects also require continuous addressing. In the future, the construction of universal treatment platforms,breakthroughs in in vivo direct editing technology, and exploration of combined therapeutic strategies will be the core development directions, promoting gene therapy towards personalized precision medicine and bringing more accessible and safer curative hope to patients with hereditary blood disorders.
利益冲突:作者均声明无利益冲突

再生医学研究 Copyright © 2026. All Rights Reserved